𝔖 Bobbio Scriptorium
✦   LIBER   ✦

A polymorphism in the growth hormone receptor is associated with height in children with Prader–Willi syndrome

✍ Scribed by Sung Won Park; Seung-Tae Lee; Young Bae Sohn; Se Hwa Kim; Sung-Yoon Cho; Ah-ra Ko; Sun-Tae Ji; Jeong-Yi Kwon; Sunghee Yeau; Kyung-Hoon Paik; Jong-Won Kim; Dong-Kyu Jin

Publisher
John Wiley and Sons
Year
2011
Tongue
English
Weight
90 KB
Volume
155
Category
Article
ISSN
1552-4825

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Growth hormone therapy and scoliosis in
Growth hormone therapy and scoliosis in patients with Prader–Willi syndrome
✍ T. Nagai; K. Obata; T. Ogata; N. Murakami; Y. Katada; A. Yoshino; S. Sakazume; Y 📂 Article 📅 2006 🏛 John Wiley and Sons 🌐 English ⚖ 130 KB 👁 2 views

## Abstract Growth hormone (GH) therapy for short stature in patients with Prader–Willi syndrome (PWS) has started worldwide, and various favorable effects have been reported. However, the possibility of progression of scoliosis arises as a new problem of the GH therapy. In this study, we analyzed

Developmental profiles in young children
Developmental profiles in young children with Prader–Labhart–Willi syndrome: Effects of weight and therapy with growth hormone or coenzyme Q10
✍ Urs Eiholzer; Udo Meinhardt; Valentin Rousson; Nelica Petrovic; Michael Schlumpf 📂 Article 📅 2008 🏛 John Wiley and Sons 🌐 English ⚖ 102 KB 👁 1 views

## Abstract Muscle hypotonia and failure to thrive are key symptoms of Prader–Willi syndrome (PWS) allowing diagnosis during infancy already. Improved general care as well as Coenzyme Q~10~ (CoQ~10~) and growth hormone (GH) are administered to improve PWS children's outcome. This study aims to inve

Amplification of the androgen receptor g
Amplification of the androgen receptor gene is associated with P53 mutation in hormone-refractory recurrent prostate cancer
✍ Koivisto, Pasi A.; Rantala, Immo 📂 Article 📅 1999 🏛 John Wiley and Sons 🌐 English ⚖ 257 KB 👁 2 views

p53 protein expression of 30 hormone-refractory locally recurrent prostate cancers was compared with their matched untreated primary tumour specimens. In addition, androgen receptor (AR) gene amplification and p53 protein immunostaining were compared. p53 positivity increased during hormonal therapy